TreVita, a U.S.-based medical travel company, has announced the expansion of its regenerative medicine program in Zona Río, Baja California, Mexico, broadening its stem cell services to additional therapeutic areas including healthy aging and rejuvenation, and sports and orthopedic injuries. The move positions the company to capitalize on the rapidly growing U.S. regenerative medicine market, which Grand View Research estimates generated approximately $19.5 billion in 2024 and is projected to reach $49.3 billion by 2030, growing at a compound annual rate of about 16.8% from 2025 through 2030.
The expansion emphasizes individualized physician evaluation over predetermined treatment packages. Under the program, physicians assess a client's medical history, current condition, diagnostic information, and treatment goals to determine candidacy and the appropriate approach. A central focus is transparency around cellular products, including cell type and source, cell count, viability, and delivery method, with testing and documentation provided to each client. TreVita also offers end-to-end support spanning physician consultations, medical records and diagnostic review, treatment planning, travel logistics, care coordination, and post-treatment follow-up.
"Regenerative medicine is an increasingly important part of the healthcare conversation, but it is also a category where clients need clarity, transparency and strong medical oversight," said Blake Schroeder, CEO of TreVita. "Our goal is to help clients understand their options, remove barriers, connect them with experienced physicians and create a care experience built around safety, care, integrity and support - and most importantly, increased healthspan."
For readers in Long Beach and the surrounding area, the expansion could signal greater access to regenerative therapies for conditions such as orthopedic injuries and age-related decline. As Americans seek new approaches to health, recovery, and longevity, TreVita's physician-led model aims to provide a safer, more transparent alternative to unregulated stem cell clinics. The company is also developing additional clinical and laboratory capabilities in Zona Rio, which will allow greater oversight of cellular quality and follow-up care.
The announcement, made via NEWMEDIAWIRE, reflects a broader trend of medical travel companies building integrated platforms that connect physicians, science, and patient experience. TreVita, headquartered in San Diego, partners with vetted physicians in Mexico and other global destinations for bariatric surgery, plastic surgery, hair transplant, and regenerative medicine. Its focus on transparency and accountability may help set new standards in an industry where patients often lack clear information about the cellular products they receive.
As the regenerative medicine market continues its double-digit growth, TreVita's expansion underscores the increasing demand for innovative solutions that prioritize safety and individualized care. For those considering regenerative options, the program's emphasis on realistic expectations and physician oversight could provide a more reliable pathway. More information about TreVita's services is available at TreVita.
